



CardioDx Announces Participation in Lazard Capital Markets and Piper Jaffray Investor Conferences

PALO ALTO, Calif. – November 12, 2012 – CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced participation in two upcoming investor conferences.

David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and of Corus[®] CAD, the only clinically validated gene expression test for obstructive coronary artery disease, at the Lazard Capital Markets 9th Annual Healthcare Conference at 2:30 p.m. ET on Tuesday, Nov. 13, at the Pierre Hotel in New York. He also will present at the 24th Annual Piper Jaffray Healthcare Conference at 10:10 a.m. ET on Tuesday, Nov. 27, at the New York Palace Hotel.

Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists exclude obstructive coronary artery disease (CAD) as the cause of a stable nondiabetic patient's symptoms. The test involves a routine blood draw conveniently administered in the clinician's office, and does not expose patients to risk of radiation or imaging agent intolerance. It is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has now been used to assess more than 31,000 U.S. patients.

In August 2012, Medicare coverage was established for the Corus CAD gene expression test for evaluating patients presenting with typical and atypical symptoms suggestive of coronary artery disease, making the test a covered benefit for more than 40 million Medicare enrollees in the U.S.

Corus CAD has also been recognized by *The Wall Street Journal's* Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of *TIME's* Top Ten Medical Breakthroughs. CardioDx was recently honored as one of *FierceMedicalDevices'* "Fierce 15" most promising privately held medical device and diagnostic companies.

About CardioDx

CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.

###

Media Contact:

Nicole Osmer
650.454.0504
nicole@nicoleosmer.com

